

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Biomedical Sciences Investment Fund Pte Ltd.</u> (Last) (First) (Middle) 20 BIOPOLIS WAY #09-01 (Street) SINGAPORE 138668 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/12/2006	3. Issuer Name and Ticker or Trading Symbol <u>Vanda Pharmaceuticals Inc. [VNDA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,480 ⁽⁵⁾	I	See Footnote ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series A Preferred Stock	(2)	(3)	Common Stock 1,479,867 ⁽⁵⁾	(6)	I	See Footnote ⁽¹⁾
Series B Preferred Stock	(2)	(3)	Common Stock 1,091,321 ⁽⁵⁾	(4)	I	See Footnote ⁽¹⁾

1. Name and Address of Reporting Person*
Biomedical Sciences Investment Fund Pte Ltd.
 (Last) (First) (Middle)
 20 BIOPOLIS WAY
 #09-01
 (Street)
 SINGAPORE 138668
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Bio One Capital Pte Ltd.
 (Last) (First) (Middle)
 20 BIOPOLIS WAY
 #09-01
 (Street)
 SINGAPORE 138668
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
EDB Investments Pte Ltd.
 (Last) (First) (Middle)
 20 BIOPOLIS WAY
 #09-01

(Street)

SINGAPORE

138668

(City)

(State)

(Zip)

Explanation of Responses:

1. Securities owned directly by Biomedical Sciences Investment Fund Pte Ltd. These securities may be deemed to be beneficially owned by Bio*One Capital Pte Ltd. ("BioOne"), the fund manager of BioMedical Science Investment Fund PTE LTD ("BSIF") and EDB Investments Pte Ltd. ("EDB"), the parent company of BSIF and BioOne. Each of BioOne and EDB disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that BioOne or EDB is the beneficial owner of the securities for any purpose, except to the extent of its pecuniary interest therein.
2. Immediately.
3. Not applicable.
4. Reflects the automatic conversion of each share of Series B Preferred Stock into one share of Common Stock to occur upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.
5. Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
6. Reflects the automatic conversion of each share of Series A Preferred Stock into one share of Common Stock to occur upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.

/s/ Sze Kuan Sim, Authorized 04/12/2006
Signatory

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

STATEMENT APPOINTING DESIGNATED FILER
AND

AUTHORIZED SIGNATORY

April 12, 2006

Each of the entities listed on SCHEDULE A attached hereto (each a "Reporting Person") hereby authorizes and designates Biomedical Sciences Investment Fund Pte. Ltd. (the "Designated Filer"), to prepare and file on behalf of such Reporting Person individually, or jointly together with other Reporting Persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that such Reporting Person may be required to file with the United States Securities and Exchange Commission or with any regulatory body, including United States federal, state and self-regulatory bodies, with respect to the Reporting Person's ownership of, or transactions in, the securities of any entity whose securities are beneficially owned (directly or indirectly) by such Reporting Person (collectively, the "Reports").

Each Reporting Person hereby further authorizes and designates Sze Kuan Sim (the "Authorized Signatory") to execute and file on behalf of such Reporting Person the Reports and to perform any and all other acts, which in the opinion of a Designated Filer or such Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted.

The authority of the Designated Filer and Authorized Signatory under this document with respect to each Reporting Person shall continue until such Reporting Person is no longer required to file any Reports with respect to the Reporting Person's ownership of, or transactions in, securities, unless earlier revoked in writing. Each Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person's responsibilities to comply with any United States federal or state law or with any regulations promulgated thereto.

SCHEDULE A

BIOMEDICAL SCIENCES INVESTMENT FUND PTE. LTD.
BIO*ONE
CAPITAL PTE LTD.
EDB INVESTMENTS PTE LTD.

In Witness Whereof,
the undersigned have caused this Statement
Appointing Designated Filer
and Authorized Signatory to be effective
as of April 12, 2006.

Reporting Persons:

April 12, 2006

BIOMEDICAL SCIENCES
INVESTMENT FUND PTE. LTD.

By: /s/ Chu Swee Yeok

Name:

Chu Swee Yeok

Title: Director

April 12, 2006

BIO*ONE CAPITAL PTE LTD.

By: /s/ Chu Swee Yeok

Name:

Chu Swee Yeok

Title: Chief Executive Officer

April
12, 2006

EDB INVESTMENTS PTE LTD.

By: /s/ Anna Chan

Name: Anna Chan

Title: Director Investments

JOINT FILER INFORMATION

Joint Filer Name:
Bio*One Capital Pte Ltd.

Relationship to Issuer: 10% Owner

Address: 20 Biopolis Way, #09-01 Centros, Singapore 138668

Designated Filer: Biomedical Sciences Investment Fund Pte Ltd.

Date of Event
Requiring Statement: April 12, 2006

Issuer Name
and Ticker
or Trading Symbol: Vanda Pharmaceuticals, Inc. (VNDA)

Signature Bio*One Capital Pte Ltd.

By: /s/ Sze Kuan Sim

Sze Kuan Sim,

Authorized Signatory

Joint Filer Name: EDB Investments Pte Ltd.

Relationship to Issuer: 10% Owner

Address: 20
Biopolis Way, #09-01 Centros, Singapore 138668

Designated Filer:
Biomedical Sciences Investment Fund Pte Ltd.

Date of Event
Requiring Statement: April 12, 2006

Issuer Name and Ticker
or
Trading Symbol: Vanda Pharmaceuticals, Inc. (VNDA)

Signature EDB
Investments Pte Ltd.

By: /s/ Sze Kuan Sim

Sze Kuan Sim, Authorized

Signatory